CGTN America & CCTV UN: China Sci-Tech Innovation Gala showcases breakthroughs
On December 30, 2024, China Media Group (CMG) debuted the "China Sci-Tech Innovation Gala," a science and technology festival, featuring "new quality productive forces".
WASHINGTON, Jan. 8, 2025 /PRNewswire-PRWeb/ -- On December 30, 2024, China Media Group (CMG) debuted the "China Sci-Tech Innovation Gala," a science and technology festival, featuring "new quality productive forces".
CMG says it will plan more innovative programs to tell the stories of China's scientific and technological innovation to the world.
The gala brings together the best innovations of the year and interprets the "inspiring soul" of science and technology in an imaginative way.
Featuring robotic bands, virtual hosts, drones, and breakthroughs in AI, brain-computer interfaces, and space exploration, the event brought innovation to life.
Click here for more about https://newsus.cgtn.com/news/2025-01-08/China-Sci-Tech-Innovation-Gala-showcases-breakthroughs-1zZ7oY2OTPW/p.html
FOR IMMEDIATE RELEASE. (This material is distributed by MediaLinks TV, LLC on behalf of CCTV. Additional information is available at the Department of Justice, Washington, D.C.)
Media Contact
Zeng Siwei, CGTN America, 1 2023931850, [email protected]
View original content:https://www.prweb.com/releases/cgtn-america--cctv-un-china-sci-tech-innovation-gala-showcases-breakthroughs-302345988.html
SOURCE CGTN America
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
- Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
- Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share